Samsung Biologics and Pfizer announce US$411M collaboration for biosimilar manufacturing in Korea

Jun 8, 2023

Samsung Biologics and Pfizer announced that they have entered a new long-term strategic partnership for manufacturing of Pfizer’s biosimilars portfolio.  According to a Samsung Biologics company filing, the contract is worth US$411M.  Using its newest facility, Plant 4, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing of biosimilars covering oncology, inflammation, and immunology.

This news comes only days after Samsung Biologics announced it will accelerate the timeline for construction and operations of its new, fifth manufacturing plant.

Print Page Mail Article